Stay updated on Ixazomib Combo in Relapsed/Refractory MM Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page.

Latest updates to the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page
- Check4 days agoChange DetectedThe footer revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe footer’s site revision label was updated from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check32 days agoChange DetectedA site-wide NIH notice about terminology changes appears, and the site revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.7%

- Check46 days agoChange DetectedThe site footer now identifies the platform as revision v3.7.1 instead of v3.7.0.SummaryDifference0.1%

- Check67 days agoChange DetectedA new revision entry v3.7.0 was added to the study record history. The previous v3.6.6 entry was removed, updating the documented version history.SummaryDifference0.1%

- Check81 days agoChange DetectedA new revision entry (v3.6.6) appears in the study record history with updated status notes (e.g., Returned, Quality Control Review Has Not Concluded) and the addition of sections like Adverse Events, Outcome Measures (Results), and Participant Flow; the prior revision (v3.6.5) is removed from the history.SummaryDifference0.9%

Stay in the know with updates to Ixazomib Combo in Relapsed/Refractory MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page.